The Priority Review

Clinical trials Brief

Boryung Biopharma registers Phase 3 trial of BRC-201 in influenza

The study plans to enroll 348 participants and is expected to start in November 2026, with primary completion projected for April 2027. It is a multicenter, randomized, double-blind Phase 3 trial evaluating the efficacy and safety of BRC-201 in adult and adolescent patients with acute uncomplicated influenza.

Primary source

ClinicalTrials.gov registry record, November 17, 2026

A Study to Evaluate the Efficacy and Safety of BRC-201 in Patients With Acute Uncomplicated Influenza

Read the source: A Study to Evaluate the Efficacy and Safety of BRC-201 in Patients With Acute Uncomplicated Influenza clinicaltrials.gov

Machine-summarized from the source above; not independently reported. How we use automation